Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ephedra Rule Cites Lack Of Safety Data In Vulnerable Subjects

This article was originally published in The Tan Sheet

Executive Summary

Research weighed by FDA in evaluating the safety of ephedrine alkaloid-containing dietary supplements was lacking in subjects that were adequately representative of the broader population, the agency maintains in the 1final rule banning the botanical

You may also be interested in...



Synthetics Stance In NDI Guidance Raises Red Flag For Industry

FDA's draft guidance on new dietary ingredient notifications already is arousing fierce pushback from the supplement industry over what constitutes an NDI and which substances cannot be dietary ingredients at all.

Synthetics Stance In NDI Guidance Raises Red Flag For Industry

FDA's draft guidance on new dietary ingredient notifications already is arousing fierce pushback from the supplement industry over what constitutes an NDI and which substances cannot be dietary ingredients at all.

Synthetics Stance In NDI Guidance Raises Red Flag For Industry

FDA's draft guidance on new dietary ingredient notifications already is arousing fierce pushback from the supplement industry over what constitutes an NDI and which substances cannot be dietary ingredients at all.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS096475

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel